Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antiscorpion venom serum is a biologic antivenom used for the treatment of clinical signs and symptoms resulting from envenomation by scorpions. It consists of refined antibodies derived from equine (horse) plasma that has been immunized with specific scorpion venoms. The preparation is typically freeze-dried and reconstituted before intravenous administration. The mechanism of action involves the passive transfer of antibodies that bind to and neutralize neurotoxins present in the scorpion venom, thereby preventing these toxins from interacting with their physiological targets in the body[1][2][3][4]. This leads to rapid resolution of systemic symptoms such as muscle control loss, abnormal eye movements, respiratory distress, excessive salivation, vomiting, and other neurological manifestations[3][4]. Antiscorpion venom serums are indicated for moderate to severe cases of envenomation where systemic toxicity is evident. Severe hypersensitivity reactions can occur due to its equine origin; thus monitoring during administration is required[3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on antiscorpion venom serum.